Lyle R Petersen1, Aaron C Brault, Roger S Nasci. 1. Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, US Public Health Service, Department of Health and Human Services, Fort Collins, Colorado 80521, USA. lxp2@cdc.gov
Abstract
IMPORTANCE: Since its introduction in North America in 1999, West Nile virus has produced the 3 largest arboviral neuroinvasive disease outbreaks ever recorded in the United States. OBJECTIVE: To review the ecology, virology, epidemiology, clinical characteristics, diagnosis, prevention, and control of West Nile virus, with an emphasis on North America. EVIDENCE REVIEW: PubMed electronic database was searched through February 5, 2013. United States national surveillance data were gathered from the Centers for Disease Control and Prevention. FINDINGS: West Nile virus is now endemic throughout the contiguous United States, with 16,196 human neuroinvasive disease cases and 1549 deaths reported since 1999. More than 780,000 illnesses have likely occurred. To date, incidence is highest in the Midwest from mid-July to early September. West Nile fever develops in approximately 25% of those infected, varies greatly in clinical severity, and symptoms may be prolonged. Neuroinvasive disease (meningitis, encephalitis, acute flaccid paralysis) develops in less than 1% but carries a fatality rate of approximately 10%. Encephalitis has a highly variable clinical course but often is associated with considerable long-term morbidity. Approximately two-thirds of those with paralysis remain with significant weakness in affected limbs. Diagnosis usually rests on detection of IgM antibody in serum or cerebrospinal fluid. Treatment is supportive; no licensed human vaccine exists. Prevention uses an integrated pest management approach, which focuses on surveillance, elimination of mosquito breeding sites, and larval and adult mosquito management using pesticides to keep mosquito populations low. During outbreaks or impending outbreaks, emphasis shifts to aggressive adult mosquito control to reduce the abundance of infected, biting mosquitoes. Pesticide exposure and adverse human health events following adult mosquito control operations for West Nile virus appear negligible. CONCLUSIONS AND RELEVANCE: In North America, West Nile virus has and will remain a formidable clinical and public health problem for years to come.
IMPORTANCE: Since its introduction in North America in 1999, West Nile virus has produced the 3 largest arboviral neuroinvasive disease outbreaks ever recorded in the United States. OBJECTIVE: To review the ecology, virology, epidemiology, clinical characteristics, diagnosis, prevention, and control of West Nile virus, with an emphasis on North America. EVIDENCE REVIEW: PubMed electronic database was searched through February 5, 2013. United States national surveillance data were gathered from the Centers for Disease Control and Prevention. FINDINGS:West Nile virus is now endemic throughout the contiguous United States, with 16,196 humanneuroinvasive disease cases and 1549 deaths reported since 1999. More than 780,000 illnesses have likely occurred. To date, incidence is highest in the Midwest from mid-July to early September. West Nile fever develops in approximately 25% of those infected, varies greatly in clinical severity, and symptoms may be prolonged. Neuroinvasive disease (meningitis, encephalitis, acute flaccid paralysis) develops in less than 1% but carries a fatality rate of approximately 10%. Encephalitis has a highly variable clinical course but often is associated with considerable long-term morbidity. Approximately two-thirds of those with paralysis remain with significant weakness in affected limbs. Diagnosis usually rests on detection of IgM antibody in serum or cerebrospinal fluid. Treatment is supportive; no licensed human vaccine exists. Prevention uses an integrated pest management approach, which focuses on surveillance, elimination of mosquito breeding sites, and larval and adult mosquito management using pesticides to keep mosquito populations low. During outbreaks or impending outbreaks, emphasis shifts to aggressive adult mosquito control to reduce the abundance of infected, biting mosquitoes. Pesticide exposure and adverse human health events following adult mosquito control operations for West Nile virus appear negligible. CONCLUSIONS AND RELEVANCE: In North America, West Nile virus has and will remain a formidable clinical and public health problem for years to come.
Authors: Katherine B Gibney; Robert S Lanciotti; James J Sejvar; C Thomas Nugent; Jeffrey M Linnen; Mark J Delorey; Jennifer A Lehman; Erin N Boswell; J Erin Staples; Marc Fischer Journal: J Infect Dis Date: 2010-12-15 Impact factor: 5.226
Authors: Steven A Baty; Katherine B Gibney; J Erin Staples; Andrean Bunko Patterson; Craig Levy; Jennifer Lehman; Tricia Wadleigh; Jamie Feld; Robert Lanciotti; C Thomas Nugent; Marc Fischer Journal: J Infect Dis Date: 2012-03-20 Impact factor: 5.226
Authors: Paula A Macedo; Jerome J Schleier; Marcia Reed; Kara Kelley; Gary W Goodman; David A Brown; Robert K D Peterson Journal: J Am Mosq Control Assoc Date: 2010-03 Impact factor: 0.917
Authors: James J Sejvar; Aaron T Curns; Leonie Welburg; James F Jones; Louisa M Lundgren; Lucile Capuron; John Pape; William C Reeves; Grant L Campbel Journal: J Neuropsychol Date: 2008-09 Impact factor: 2.864
Authors: Michael P Busch; Steven H Kleinman; Leslie H Tobler; Hany T Kamel; Philip J Norris; Irina Walsh; Jose L Matud; Harry E Prince; Robert S Lanciotti; David J Wright; Jeffrey M Linnen; Sally Caglioti Journal: J Infect Dis Date: 2008-10-01 Impact factor: 5.226
Authors: Nicholas Komar; Stanley Langevin; Steven Hinten; Nicole Nemeth; Eric Edwards; Danielle Hettler; Brent Davis; Richard Bowen; Michel Bunning Journal: Emerg Infect Dis Date: 2003-03 Impact factor: 6.883
Authors: Jaclyn A Kaiser; Huanle Luo; Steven G Widen; Thomas G Wood; Claire Y-H Huang; Tian Wang; Alan D T Barrett Journal: Vaccine Date: 2019-10-11 Impact factor: 3.641
Authors: Terza Brostoff; Patricia A Pesavento; Christopher M Barker; Joan L Kenney; Elizabeth A Dietrich; Nisha K Duggal; Angela M Bosco-Lauth; Aaron C Brault Journal: Vaccine Date: 2016-09-13 Impact factor: 3.641
Authors: Nicholas J Barrows; Rafael K Campos; Kuo-Chieh Liao; K Reddisiva Prasanth; Ruben Soto-Acosta; Shih-Chia Yeh; Geraldine Schott-Lerner; Julien Pompon; October M Sessions; Shelton S Bradrick; Mariano A Garcia-Blanco Journal: Chem Rev Date: 2018-04-13 Impact factor: 60.622
Authors: Duke J Ruktanonchai; Shelley Stonecipher; Nicole Lindsey; Janet McAllister; Satish K Pillai; Kalanthe Horiuchi; Mark Delorey; Brad J Biggerstaff; Tom Sidwa; James Zoretic; Roger Nasci; Marc Fischer; Susan L Hills Journal: Am J Trop Med Hyg Date: 2014-04-28 Impact factor: 2.345
Authors: Marta S Shocket; Anna B Verwillow; Mailo G Numazu; Hani Slamani; Jeremy M Cohen; Fadoua El Moustaid; Jason Rohr; Leah R Johnson; Erin A Mordecai Journal: Elife Date: 2020-09-15 Impact factor: 8.140